Organogenesis Holdings Inc.

ORGO· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$2.34-1.27%

2026-08-03

Financials

Valuation Metrics

Organogenesis Holdings Inc.'s Market Cap is $301M. At end of 2025 it was $657M. Ranked #2961 of 3,112 in US market (top 95%), #1329 of 1,445 on NASDAQ (top 92%), #242 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$301M	US#2,961/3,112 Sec#242/269
Revenue	$514M	US#2,334/3,112 Sec#80/269
Net Income	$-284000.00	US—/3,112 Sec—/269
Total Assets	$520M	US#2,724/3,112 Sec#150/269
Net Assets	$381M	US#2,429/3,112 Sec#141/269
Value
P/B	0.79x	US#196/3,112 Sec#6/269
P/S	0.59x	US#342/3,112 Sec#5/269
EV/EBITDA	7.50x	US#415/3,112 Sec#16/269
FCF Yield	5.67%	US#1,146/3,112 Sec#41/269
Profitability
ROE	-0.07%	US#2,158/3,112 Sec#74/269
ROA	-0.05%	US#2,214/3,112 Sec#74/269
Op. Margin	2.14%	US#2,303/3,112 Sec#82/269
Revenue Growth	-57.06%	US#2,886/3,112 Sec#164/269
Earnings Growth	4201.05%	US#9/3,112 Sec#2/269
Financial Health
Debt Ratio	36.36%	US#415/3,112 Sec#117/269
Total Debt	$71M	US#2,471/3,112 Sec#139/269
FCF	$17M	US#2,163/3,112 Sec#76/269
Cash	$92M	US#2,269/3,112 Sec#184/269
Current Ratio	3.53x	US#661/3,112 Sec#180/269
Net Debt/EBITDA	-0.57x	US#434/3,112 Sec#28/269
Performance
1Y Return	-48.12%	US#2,967/3,112 Sec#245/269
1M Return	-0.85%	US#1,765/3,112 Sec#87/269
From 52W High	-66.95%	US#2,997/3,112 Sec#250/269
1Y MDD	-65.75%	US#2,849/3,112 Sec#237/269
Trading
Volume	758,944 shares	US#1,736/3,112 Sec#170/269
Trading Value	$2M	US#2,943/3,112 Sec#248/269
Per Share
EPS	$0.29	US#1,939/3,112 Sec#67/269
BPS	$3.42	US#2,379/3,112 Sec#155/269